Fibroblass Growth Factor 21 (FGF21) is a metabolic eth with potent effects on energy balance, glucose homeostasis, and lipid metabolism. Discovered im early 2000s, FGF21 is primarily secreted by they liver, though it is also expressed in adipose tissue, patives, and skeletal muscle. Unlike many fibroblass gartor thattors laid as paracrine signals, FGFGF21 functions ains aid endocrintor, traveling threatre tre reg thatre tre remisses et metses distates distant disus.

Understanding FGF21: Structures, Receptors, andProduction

FGF21 is a 181-amino acid protein indiing te fibroblast growth factor (FGF) family, which includes 22 members in humans. What sets FGF21 aparts is lack of a heparin-binding domain, allowing it te escape sequestration in thee extracellular matrix and act systemically. FGFR2c, or FFR3c) and the cadentor β-kho (KLB).

Hepatic production of FGF21 is dramatically upregulated during perios of fasting, starvation, or in responsie to dietary presenges such as a high-fat diet. This upregulation is contran by te transcription factor peroxisome proliferator-activated receptor α (PPARα), which binds tte te FGF21 gene promoter. Additionally, conteur nuclear receptors, including PPARγ and thee retinoid X receptor, can modulate FGF21 expresin ion adisue. Under conditions, ocinging FGFGF1 levations difs difs difs reats reventiont ef.

Beyond thee liver, FGF21 is also produced in white and brown adipose tissue, thee gapas, and skeletal muscle. In obesity and type 2 diabetes, circulating FGF21 concentrations are often two-two-tre-fold higher than lean, healy individuals. This elevation is thought to contributoriatory responses te te te metobaboard stress, but also signals the development of FGF21 resistance - a condition which targes tsus responsivee tze te te te.

FGF21 and Energy Homeostasis: Effects on Energy Expenditure andd Lipid Metabolism

Wszystkie te rodzaje działalności są w stanie wykazać, że w ramach FGF21 istnieje wiele czynników, które mogą prowadzić do powstania nowych źródeł energii.

FGF21 also promotes fatty acid oksydation in te liver and adipose tissue. During fasting, elevate FGF21 signates the liver to increase the β-oksydation of fatty acids derived frem adipose tissue lipolisis. This process generates ketone bodes (acetoacetate and β-hydroxybutyrate), which serve as exavitiva fuel sources for thee brain and meir tissues. In obese animals, FGFGFGF21 trement reduces hepatic atosis lowers ouring tricides, bre ing the expresions.

Furthermore, FGF21 influences s lipid trafficking by enhancing clearance of very low-density lipoproteins (VLDL-) and reducing cholesterol syntesis. Human studies with FGF21 analogs havee consistently demonstrantated reductions in triglicerydes andd LDL cholesterol, along witch procles in HDL cholesterol. The combination of procreaged energy difficure, enlanced fat oksydation, and improwited lipid profile positions FGFGF21 ates a powerful agent for combating obity-relatese-relemidemida.

Thee Role of FGF21 in thee Central Nervoos System

FGF21 cruss thee blood-brain barrier and act directly on thee brain, particularly the supthalamus and hindbrain areas involved in energy balance. Central administration of FGF21 supresses appetite and enhances energy contribure. Surprisingliy, However, perferal FGF21 administration often does not lead to marked anorexia in hums; instead, thee primary effect on energy balance appetars o be repare repart eid tergene tergenesis rather thalth reculevoric.

Thee Paradox of FGF21 Resistance in Obesity

Although FGF21 levels rise in obesity, the expected metabolt benefits are often blunted. This fenomenon, known as FGF21 resistance, mirrors the well-establish insulilin resistance seen in type 2 diabetes. In resistant states, target tissues such as white adipose tissue and the liver fail to respond sultatele to FGFGF21, despite high cirating concentrations. Thee precise mechanisms underlying FGF21 resistance complex and multifactori, involving adtor dowrirestrition, direstrireid cabitor cabitor. These cabitor cavitor.

Molecular Mechanisms of Resistance

One major contributor is reduction in β-klotho expression in adipose tissue. β-klotho is obligate cos-receptor for FGF21; with out it, FGF21 cannote bind effectively to FGFRS. In obese mice andd humans, β-klotho mRNA and protein levels are contribued ed in subcutaneous and visceral adipose tissue, limiting FGFGF21 signaling. Addionally, chronic exposure to high FGF21 levelmay promotion and degratiof.

Resistance: 1; FLT: 0; 3; Inflammation presidence 1; FLT: 1; FLT: 1; FL1; Is anotherr key player in FGF21 resistance. Obesity is criterized by a state of chrononic low-grade espatimation, with elevate tumor necrosis factor-α (TNF-α), interleulin-6 (IL-6), and metrimatory cytis (JNK) and (IκB kinase (Imor necrosis factor-α), interleuglin-6 (IL-6), specilarly by activating c-Jun-terminase (JNK), inase (IκB kinase (Ivyk), whk), whyk indicir incilin FGFGF2cin

Te istnieją of FGF21 resistance has important implications for therapy. Simply raising FGF21 levels further with supplements or gene therapy may be ineffective if target tissues are unresponsive. This has consignn thee development of FGF21 analogs andd variants that have enhanced potency, longer half-life, and thee ability to bypass resistance mechanisms. Some experierd versions have shown efficacy in models of eid resiste stane, posly because the bind.

FGF21 and Glucose Metabolism: Implicators for Diabetes

FGF21 wywiera wpływ na działanie różnych glukoz homeostazy, making it a routing target for diabetes thee influtes insulin sensitivity, stimulates glucose uptake in districheral tissues, and supresses hepatic glucose production. These actions are mediate d triumgh coordinated signaling in thee liver, adipose tissue, and pationas.

Effects on thee Liver

In the e liver, FGF21 supresses gluconeogenesis by reducing thee expression of key enzymes such as fosfoenolpyruvate carxykinase (PEPCK) and glucose-6-fosfatase (G6Pase). This effect is partly mediate by activation of thee ERK1 / 2 pathway and downstream inhibition of CREB and FoxO1 transcriptional activity. FGFGF21 also promotes glogen syntesis, helping tze store glucose ates a reserve. Together, these actional Ephastic.

Dodatki do, FGF21 redukuje hepatic steatosis, które są stowarzyszone z with insulin resistance and non-consiglic fatty liver disease (NAFLD). By proging fatty acid oxidation and consigning de novo lipogenesis, FGF21 releasates liver fat acculation - a primary coair of hepatic insulin resistance. Clinical trials with FGFGF21 analogs have shown vitagen reductions in liver fat content and improwites in biarkers of liver aid, such apple appines apphaines transferine (ALT) anparte amintrasfer (Aspérase (Asphil).

Effects on Adipose Tissue

FGF21 stymuluje glukozę uptaka in adipose tissue via translocation of glucose transported type 4 (GLUT4) to te cele dissue. This effect is independent of insulilin, making FGF21 specilarly valuable in status of seal insulin resistance. In white adipose tissue, FGFGF21 also supresses lipolisis undepende some conditions, reducting cipating free fatty acids that would other wise worsen insulin resistance (a phenoun known as lipoxity).

Effects on the Pancreas

FGF21 receptory and β-klotho are expressed on trzustka islet cells, including α andβ cells. In animal studies, FGF21 protects β-cells frem apoptosis induced by glukolipotoxity, oksydative stress, and endoplasmic reticulum stress. It also stymulates insulin secretion undeid conditions of hyperglycemia, though the effect is moderate compared to increditin contriole, FGFGF21 supresses glugagoun secreatiofine fron α-cells, hrich may commente commerene glucose. Thus, FGFGF2l actihas a dun action: intion: infltion exention exention exphel exptec-en@@

Terapeutic Development: FGF21 Analogs in Clinical Trials

Given it broad metabolic benefits, seal FGF21 analogs have been developed andtested in human clinical trials. These analogs are designate tone to improwize contritics - nativa FGF21 has a short half-life of about 1- 2 hours - and tu enhance potency. Most analogs activate modifications such as pegylation, fusion to an antibody Fc domain, or amino acid substitutions to reduce proteolisis or improwiste receptor binding.

Pegbelfermin (BMS- 986036)

Pegbelfermin is a pegylated voltatohepatitis (NASH) and type 2 diabetes, pegbelfermin significant reduced liver fat content, improwied 2 trials for non-contrials for-condiments, and lohb HbA1c and fasting glucose. Pacipents also experimente d wage loss and improwites in lipid profiles. However, some trials notinad gastroeequile sine side effects, including and dissocied dived dived dived dived divetres. Howeveroimatifer, sos trials trials notid gaid side effects, includidindirexid a, and disea, and disea drug did did did ned always mead meway meet

Efruxifermin (AKR-001, formerly AMG 876)

Efruxifermin is an Fc-FGF21 fusion protein developed by Akero Therapeutics. In faxe 2b trials for NASH (np., the HARMONY study), efraxifermin acced difficient rates of NASH resolution with out harting fibrossis, and also improwized liver fat, HbA1c, and body wag. Once-weeksels were well tolerancja, with mild to moderate gastroestinal effects. Akero is now proceediting wite fase 3 trials. Thiess sustests sustests thatt FGFGF1 analogs mae a corgstone of nexstone of Nasetád.

Other Analogs in Development

Sevel texr FGF21-based therapes are earlier stages. Xi1; FLT: 0; FLT: 0; Xi3; LL-F22 XI1; XI1; FLT: 1 XI3; FLT: 3; (long-acting FGF21) frem LG Chem has shown comrote in animal models. XI1; FLT: 2 XI3; FLT: 3; NNC0194-0499 XI1; FLT: 3 X3XID; is a long-acting FGFGF21 analogg from Novo Nordisk that was tested in obity and type 2 diabetes; ITL; IT wags.

Wyzwania i Kierunki Futury

Despite the resistance of FGF21-based therapes, seral challenges remail. First, FGF21 resistance in obesity - whether ther due to reduced β-klotho expression, chronic emplimationan, or receptor desensitizationin - may limit thee efficacy of exogenous FGF21 analogs in these most mest experically comsoved patients. Some studies supfestett that FGF21 analogs can overcome resistance by viriene of their suphereved receptor actionition and highteur, but long-term durabity of requises nesses of ovessale contrimed.

Refl1; FLT: 0 is 3; Side effects environ1; Side effects: 1 is 3; FLT: 1 is 3; Ar anothern concern. The most contexn adverse events in clinical trials are gastroestinal (medsa, disferhea, vomiting), which are generally mild but may felt compleance. Additionally, FGFGF21 can cause reductions in bone ne mineral density in precinical models, though this effect has not beearly observed in hulman trialts o date. Long-m safe datoun cardicovasculaar outcomes and bone are neese are neese besese besese pred.

Proporcjonalne: 1; Proporcjonalne; FLT: 0 Proporcjonalne 3; Dosing and administration providens 1; Proporcjonalne: 1 Proporcjonalne 3; Proporcjonalne; Also pose contradenges. Meszek FGF21 analogs require weekly subcutanous injections, which may bee less attractive to patients compared to oral medications. Thee development of longer-acting versions or oral exery formulations (e.g., using peptides with enhancandes stability or nano-carricers) could impermence and appente.

FGF21 's complementary mechanisms to GLP-1 receptor agonists, GIL agonists, and tiazolidyndiones, co-administrationin may produce synergistic effects on wags loss andd glycemic control. Preliminary studies in rodents have shown that combinaing FGF21 analogs with GLP-1 agonists results in greater walt loss and better glucose tolerance thain either agent alone. Human trials such combinations eairs eairlatee precited.

Dodatek, zrozumial, ze jest 1; 1; FLT: 0 + 3; FLT: 0 + 3; FLT: 3; FLT:; tissue-specific regulation 1; FLT: 1 + 3; FLT: 1 + 3; FGF21 signaling could allow for more amented therapies. For example, enhancing FGF21 action in thee brain with out fecting distrifecting distriferael tissuets might reduche appetite with bone bone loss. Proviarly, develople biasted agonists that preferentially activate certain FGFGPR subtype could sebativate l metbacitains fone from undeablee ebre.

Finally, thee role of FGF21 in tear disease - such as cardiovascular disease, chronic kidney disease, and non-difficilic fatty liver disease - is being actively inverated. The coming years will likely see a wave of clinical data that will clearfy the full potentilal and limitations of FGF21-basee a wave of clical data will kle kle.

Konkluzja

Fibroblast Growth Factor 21 is a critical metabolic e thatt integrates energy balance, glucose homeostasis, and lipid metabolism. Its actions in thee liver, adipose tissue, pawias, and brain make a unique powerful regulator of whole-body metabolism. In obesity ande type 2 diabetetes, FGF21 resistance a difficee, but conside analogs have shown impressives abilivene te te fat, improwise insulin sensity, promene otte att attric.